PRESS RELEASE
By: NewMediaWire
October 2, 2024
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
ATLANTA, Ga. - (NewMediaWire) - October 02, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY. Senior GeoVax management will also host one-on-one meetings with registered attendees.
Panel Details:
Title:
Innovative Therapies for Solid Tumors
Presenter:
David Dodd, Chairman & CEO
Date/Time:
October 9, 2024, 12:30 pm ET
If you are interested in arranging a 1x1 meeting request with management, please contact your ROTH representative, or please contact the company directly at info@geovax.com.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Company Contact:
Investor Relations Contact:
Media Contact:
austin.murtagh@precisionaq.com
678-384-7220
212-698-8696
202-779-0929
This press release is distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference.
